CEO leaning into the promise of AI for biotech? Not so fast, it can hurt firm value
Healthcare CEOs that “over-hype” coming innovations suddenly or inconsistently are punished by shareholders - unless they can follow it up with results well beyond industry averages.
To maximize Series A runway, biotech investors must look for this key trait
To get to Series B, biotechs must kill dead-end projects fast: prior success + failure predict which shave years of waste
Simple criteria for a biopharma to never lose licensing deals post-acquisition
Biotech R&D partnerships (and potential fees) get lost post-acquisition - learn how to screen for firms that will keep them
A little customer focus goes a long way for a biotech being acquired
Early-stage biotechs that put extra effort into customer focus are rewarded with a higher likelihood of being acquired by big pharma
Break room magic - pharma office layout has huge impact on R&D returns
Biotech’s that stop doing this to their new product development teams get huge returns
NPD teams meeting too often, or not enough, are inefficient - optimized schedules double profitability of new products.
